ViroGates raises 2026 revenue outlook to DKK 6.5 million-8 million

• ViroGates raised its 2026 revenue outlook to DKK 6.5-8 million from DKK 6-7 million.
• EBIT guidance was maintained at DKK -10 to -12 million.
• Higher revenue expectation reflects U.S. partner suPARbio taking delivery of milestone orders under the distribution agreement.
• Operating costs seen offsetting most of the revenue uplift due to staff changes and higher IVDR compliance costs.
• Revenue uncertainty flagged for H2 due to a shift toward more scalable commercial channels in other markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ViroGates A/S published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.